A Phase 1, Randomised, Double‐Blind, Placebo‐Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP ‐ 1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity
Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 5848-5859
DOI: 10.1111/dom.70794 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 20.04.2026. Verfasst von Jinlian Xie und 12 weiteren Autor:innen. Beteiligte Einrichtung: Central South University Third Xiangya Hospital Center of Clinical Pharmacology, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Obesity, Overweight, Receptors, Gastrointestinal Hormone, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit nennt 41 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University, Suzhou Alphamab Co., Ltd..
Abstract (Originalsprache)
Aims
This first‐in‐human Phase I study evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of KN069, a novel dual Glucagon‐like peptide‐1 receptor agonist (GLP‐1RA)/Glucose‐dependent insulinotropic polypeptide receptor (GIPR) antagonist in Chinese men with overweight/obesity. Materials and Methods This randomised, double‐blind trial included a single ascending dose (SAD; 12–120 mg, N = 36, 3:1 active‐to‐placebo) and a multiple ascending dose (MAD; N = 12, dose escalation 15–60 mg) phase. Safety was assessed via adverse events (AEs) and compliance. PK was analysed using a sandwich enzyme‐linked immunosorbent assay (ELISA) for Intact and Total KN069. PD included measurements of body weight, waist circumference, body mass index (BMI) and metabolic parameters. Immunogenicity was assessed by detecting anti‐drug antibodies (ADA).
Results
KN069 was well tolerated, with predominantly mild‐to‐moderate gastrointestinal adverse events. PK showed dose‐proportional exposure (12–90 mg) with a long half‐life for Total KN069 (899.74–1099.01 h). In the SAD part, preliminary dose‐dependent weight reductions were observed, with maximum early changes at Day 7 (90 mg: −4.71% vs. placebo: −0.41%) and sustained for up to 133 days. In the MAD part, Group B (60 mg) achieved a −2.57% mean weight reduction from baseline at Day 25, alongside a significant decrease in waist circumference ( p = 0.0446). Metabolic improvements included lower fasting glucose, triglycerides, uric acid and elevated insulin/C‐peptide.
Conclusions
KN069 exhibits favourable safety, long‐acting PK and preliminary dose‐dependent weight reduction alongside expected pharmacologic metabolic effects, supporting further clinical development. ClinicalTrials.gov Identifier: NCT06547775.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central South University Third Xiangya Hospital Center of Clinical Pharmacology, Changsha, Hunan, China.
- Suzhou Alphamab Co., Ltd., Suzhou, Jiangsu, China.
ORCID-Profile: Guoping Yang, Chengxian Guo
Förderung
- National Natural Science Foundation of China
- Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University
- Suzhou Alphamab Co., Ltd.
- Major Research Project for High-Level Health and Wellness Talents of Hunan Province
Zitieren
APA
Xie, J., Huang, J., Wu, Q., Deng, K., Yang, S., Yang, S., Wu, S., Yang, X., Huang, W., Dong, Y., Li, J., Yang, G., & Guo, C. (2026). A Phase 1, Randomised, Double‐Blind, Placebo‐Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP ‐ 1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity. Diabetes, Obesity and Metabolism, 28(7), 5848-5859. https://doi.org/10.1111/dom.70794
Vancouver
Xie J, Huang J, Wu Q, Deng K, Yang S, Yang S, et al. A Phase 1, Randomised, Double‐Blind, Placebo‐Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP ‐ 1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity. Diabetes, Obesity and Metabolism. 2026;28(7):5848-5859. doi:10.1111/dom.70794
BibTeX
@article{Xie2026,
author = {Xie, Jinlian and Huang, Jie and Wu, Qian and Deng, Kunhong and Yang, Shuang and Yang, Sibo and Wu, Shuting and Yang, Xiaoyan and Huang, Wenqiao and Dong, Yanrong and Li, Jing and Yang, Guoping and Guo, Chengxian},
title = {A Phase 1, Randomised, Double‐Blind, Placebo‐Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP ‐ 1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {7},
pages = {5848--5859},
doi = {10.1111/dom.70794}
}
EUVIMED